Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

  title={Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives},
  author={Jan Tack and M J Van Outryve and G. Beyens and Ren{\'e} Kerstens and Lieve Vandeplassche},
  pages={357 - 365}
Objective: To determine the efficacy, impact on quality of life (QOL) and safety of prucalopride, a selective, high-affinity 5-HT4 receptor agonist, in patients with chronic constipation. Methods: In this multicentre, randomised, placebo controlled, parallel-group, phase III study, patients with chronic constipation (two or fewer spontaneous complete bowel movements (SCBM)/week) received 2 mg or 4 mg prucalopride or placebo, once daily, for 12 weeks. The primary efficacy endpoint was the… 

Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation

Prucalopride 4 mg significantly improved patient-rated severity of constipation and effectiveness of treatment versus placebo and was safe and well tolerated in this population with OIC.

Prucalopride: A Review of Its Use in the Management of Chronic Constipation

Oral prucalopride 2 mg once daily improved bowel function to a significantly greater extent than placebo, and is an important option for use in patients with chronic constipation who have not experienced adequate relief with laxatives.

Prucalopride: A Review in Chronic Idiopathic Constipation

Oral prucalopride 2 mg/day was significantly more effective than placebo at improving bowel function, including the number of bowel movements and a range of other constipation symptoms, as well as health-related quality of life and patient satisfaction; however, no significant differences in bowel function measures were observed between pruCalopride and placebo in a 24-week trial.

Prucalopride is no more effective than placebo for children with functional constipation.

Prucalopride, although generally well tolerated, was not more effective than placebo in children with functional constipation.

Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study.

In a cohort of patients with predominantly idiopathic gastroparesis, 4 weeks of prucalopride treatment significantly improved symptoms and quality of life and enhanced gastric emptying compared with placebo.

Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials

The integrated analysis demonstrates the efficacy and safety of prucalopride in the treatment of CC in men and women.

Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief.

It was considered that the MS provided no evidence for whether prucalopride is effective or not in women with laxative-refractory chronic constipation, and long-term efficacy data, with validated estimates of quality of life incorporated in a well-founded model, would be important for an evidence-based judgement to be made.

Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation

Over the 12 weeks, plecanatide significantly improved stool consistency and stool frequency, and was well tolerated; the most common AE, diarrhea, occurred in a small number of patients.

The association between prucalopride efficacy and constipation type

Patients with all categories of constipation may respond to prucalopride, and a trial regime may be indicated regardless of the aetiology of the constipation.

Role of Prucalopride in Treating Functional Constipation and Gastroparesis: A Systemic Review

The clinical efficacy side effects of prucalopride were generally well-tolerated, and the most common adverse events reported were headache, nausea, diarrhea, and abdominal pain.



A placebo-controlled trial of prucalopride for severe chronic constipation.

Over 12 weeks, prucalopride significantly improved bowel function and reduced the severity of symptoms in patients with severe chronic constipation.

Prucalopride Is Effective in Patients with Severe Chronic Constipation in Whom Laxatives Fail to Provide Adequate Relief

Once-daily prucalopride 4 mg for 4 weeks is effective and well tolerated in patients with severe CC, and improves whole gut transit, reducing straining, softening stools and reducing time to first bowel movement.

Efficacy and Tolerability of Prucalopride in Patients with Constipation due to Spinal Cord Injury

This pilot study indicates that prucalopride can play an important role in the management of patients with CC due to SCI, and a clear dose response for treatment efficacy is shown.

Lack of Objective Evidence of Efficacy of Laxatives in Chronic Constipation

It is found that large, well-controlled, published studies whose data were comparable were lacking and better evidence is required to justify the continued expenditure of funds on laxatives by both patients and formularies.

Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder.

PRU accelerates transit through the stomach, small bowel, and colon in patients with constipation unassociated with a rectal evacuation disorder, and tends to accelerate overall colonic transit with significantly faster overall Colonic transit and ascending colon emptying with the 4-mg dose.

The Treatment of Chronic Constipation in Adults

Both fiber and laxatives modestly improved bowel movement frequency in adults with chronic constipation, and there was inadequate evidence to establish whether fiber was superior to laxatives or one laxative class was inferior to another.

Psychological Well‐Being and Symptoms in Women With Chronic Constipation Treated With Sodium Picosulphate

  • M. BengtssonB. Ohlsson
  • Medicine, Psychology
    Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
  • 2005
The use of sodium picosulphate has been restricted to a few weeks due to its potentially harmful effect on the colon. In spite of this restriction, however, many patients prefer this pharmaceutical

The treatment of chronic constipation in adults. A systematic review.

Both fiber and laxatives modestly improved bowel movement frequency in adults with chronic constipation, and there was inadequate evidence to establish whether fiber was superior to laxatives or one laxative class was inferior to another.

Quality of life in patients with different types of functional constipation.

The general well-being of patients with chronic constipation is lower than that of a comparable normal population andSymptom severity correlates negatively with perceived quality of life.

PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial

PEG 3350 patients reported less abdominal pain, straining, and pain at defecation than children using lactulose, and bad taste was reported significantly more often in the PEG group, which should be the laxative of first choice in childhood constipation.